LOGIN  |  REGISTER
Astria Therapeutics
Cue Biopharma

Baxter to Present at Barclays 27th Annual Global Healthcare Conference

February 25, 2025 | Last Trade: US$31.17 0.19 0.61

DEERFIELD, Ill. / Feb 25, 2025 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.

The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday, September 8, 2025.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page